Henry Schein (NASDAQ:HSIC – Get Free Report) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Monday.
Several other equities analysts have also commented on HSIC. TheStreet lowered Henry Schein from a “b-” rating to a “c+” rating in a report on Thursday, November 2nd. Stifel Nicolaus restated a “buy” rating and issued a $75.00 price objective on shares of Henry Schein in a research note on Monday, November 27th. Bank of America decreased their price objective on shares of Henry Schein from $76.00 to $75.00 in a research note on Monday, August 7th. JPMorgan Chase & Co. upped their price objective on shares of Henry Schein from $80.00 to $83.00 and gave the company a “neutral” rating in a research note on Wednesday, August 9th. Finally, UBS Group decreased their price objective on shares of Henry Schein from $82.00 to $75.00 and set a “neutral” rating for the company in a research note on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $79.38.
Henry Schein Stock Down 0.3 %
NASDAQ:HSIC traded down $0.23 during trading hours on Monday, hitting $69.31. The company’s stock had a trading volume of 1,207,009 shares, compared to its average volume of 922,360. The stock has a market capitalization of $9.05 billion, a P/E ratio of 20.63, a price-to-earnings-growth ratio of 2.55 and a beta of 0.84. The stock has a fifty day moving average of $69.06 and a 200-day moving average of $74.28. The company has a current ratio of 1.97, a quick ratio of 1.09 and a debt-to-equity ratio of 0.42. Henry Schein has a 52-week low of $60.01 and a 52-week high of $89.72.
Henry Schein (NASDAQ:HSIC – Get Free Report) last posted its earnings results on Monday, November 13th. The company reported $1.32 EPS for the quarter, meeting the consensus estimate of $1.32. The firm had revenue of $3.16 billion for the quarter, compared to analyst estimates of $3.21 billion. Henry Schein had a return on equity of 16.08% and a net margin of 3.51%. Henry Schein’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.15 earnings per share. On average, equities analysts forecast that Henry Schein will post 4.57 earnings per share for the current year.
Institutional Investors Weigh In On Henry Schein
A number of hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Henry Schein by 1.4% in the first quarter. Vanguard Group Inc. now owns 15,331,533 shares of the company’s stock valued at $1,336,756,000 after purchasing an additional 214,846 shares during the period. Longview Partners Guernsey LTD lifted its position in Henry Schein by 3.5% in the first quarter. Longview Partners Guernsey LTD now owns 7,263,670 shares of the company’s stock valued at $592,280,000 after purchasing an additional 248,659 shares during the period. Bank Julius Baer & Co. Ltd Zurich lifted its position in Henry Schein by 67,055.8% in the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 6,737,741 shares of the company’s stock valued at $546,431,000 after purchasing an additional 6,727,708 shares during the period. JPMorgan Chase & Co. lifted its position in Henry Schein by 1.1% in the third quarter. JPMorgan Chase & Co. now owns 4,766,305 shares of the company’s stock valued at $353,898,000 after purchasing an additional 53,506 shares during the period. Finally, American Century Companies Inc. lifted its position in Henry Schein by 7.3% in the third quarter. American Century Companies Inc. now owns 4,719,088 shares of the company’s stock valued at $350,392,000 after purchasing an additional 322,649 shares during the period. Institutional investors and hedge funds own 93.31% of the company’s stock.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.